NINE MASTS CAPITAL Ltd acquired a new stake in shares of AstraZeneca Plc (NYSE:AZN – Free Report) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 8,400 shares of the company’s stock, valued at approximately $1,356,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of AZN. Amundi raised its holdings in shares of AstraZeneca by 146,574.4% in the first quarter. Amundi now owns 15,386,149 shares of the company’s stock worth $3,034,456,000 after buying an additional 15,375,659 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of AstraZeneca by 889.9% in the 1st quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock valued at $2,319,947,000 after acquiring an additional 10,742,268 shares during the last quarter. Rathbones Group PLC boosted its holdings in AstraZeneca by 106,772.0% in the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after purchasing an additional 8,047,406 shares during the last quarter. Royal Bank of Canada grew its holdings in AstraZeneca by 208.6% during the first quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after acquiring an additional 7,021,126 shares during the period. Finally, Swiss National Bank purchased a new position in AstraZeneca during the first quarter valued at approximately $1,202,714,000. 20.35% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on AZN shares. Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. CICC Research assumed coverage on shares of AstraZeneca in a report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 target price for the company. Weiss Ratings raised shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 26th. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Finally, Nordea Equity Research raised shares of AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $206.67.
Check Out Our Latest Report on AZN
AstraZeneca Price Performance
Shares of AstraZeneca stock opened at $184.66 on Monday. The firm has a market cap of $286.40 billion, a PE ratio of 26.12, a P/E/G ratio of 1.43 and a beta of 0.24. AstraZeneca Plc has a twelve month low of $153.41 and a twelve month high of $212.71. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. The business has a 50-day moving average price of $168.82 and a 200 day moving average price of $180.20.
AstraZeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $2.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The company had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same quarter in the prior year, the business posted $2.38 earnings per share. AstraZeneca’s revenue for the quarter was up 6.5% on a year-over-year basis. Sell-side analysts predict that AstraZeneca Plc will post 10.22 earnings per share for the current fiscal year.
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Stories
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
